BioCryst Invites You to Join Its Third Quarter 2000 Conference Call.Business Editors/Health & Medical Writers BIRMINGHAM, Ala.--(BW HealthWire)--Oct. 20, 2000 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) invites you to participate in a quarterly conference call to discuss third quarter 2000 financial results on Wednesday October 25, 2000. Charles E. Bugg, Ph. D., Chairman & Chief Executive Officer, will host the call at 10:00 am Eastern Time. To participate in this conference call please dial 1-800-289-0730. The call is expected to last no more than one hour and will include prepared remarks by senior BioCryst management with a subsequent question and answer period. If you are unable to participate during the live conference call, a telephone replay will be available from 1pm Eastern Time October 25 through midnight Wednesday, November 1. To access the rebroadcast in the U.S., call 1-888-203-1112 and enter PASSCODE No. 437678. International parties should dial 1-719-457-0820 and enter PASSCODE No. 437678. In addition, the call will be archived on BioCryst's Web site at www.biocryst.com. Founded in 1986, BioCryst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of pharmaceuticals for the treatment of infectious, inflammatory and cardiovascular diseases Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease and disorders. BioCryst's most advanced drug candidate, RWJ-270201 (formerly known as BCX-1812), is a neuraminidase inhibitor neuraminidase inhibitor Infectious disease Any antiviral that inhibits neuraminidase, an enzyme essential for replication of influenza and other viruses. See Influenza. designed to treat and prevent viral influenza influenza or flu, acute, highly contagious disease caused by a virus; formerly known as the grippe. There are three types of the virus, designated A, B, and C, but only types A and B cause more serious contagious infections. . The Company licensed this drug candidate to RWJPRI and Ortho-McNeil Pharmaceutical Ortho-McNeil Pharmaceutical, inc. is a pharmaceutical manufacturer based in Raritan, New Jersey, and a subsidiary of Johnson & Johnson. The company was formed from the merger of Ortho Pharmaceutical and McNeil Pharmaceutical in 1993. , Inc., both Johnson & Johnson (NYSE NYSE See: New York Stock Exchange : JNJ JNJ Johnson and Johnson (stock symbol) JNJ Journal of Nursing Jocularity ) companies. For additional information on BioCryst, visit the company's web site at www.biocryst.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion